ImmunityBio (IBRX) Common Equity: 2014-2025
Historic Common Equity for ImmunityBio (IBRX) over the last 11 years, with Sep 2025 value amounting to -$524.3 million.
- ImmunityBio's Common Equity rose 29.54% to -$524.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$524.3 million, marking a year-over-year increase of 29.54%. This contributed to the annual value of -$489.1 million for FY2024, which is 16.68% up from last year.
- Per ImmunityBio's latest filing, its Common Equity stood at -$524.3 million for Q3 2025, which was up 8.13% from -$570.7 million recorded in Q2 2025.
- In the past 5 years, ImmunityBio's Common Equity registered a high of -$158.6 million during Q2 2021, and its lowest value of -$744.2 million during Q3 2024.
- Its 3-year average for Common Equity is -$589.3 million, with a median of -$587.0 million in 2023.
- Per our database at Business Quant, ImmunityBio's Common Equity tumbled by 1,202.89% in 2021 and then rose by 29.54% in 2025.
- Over the past 5 years, ImmunityBio's Common Equity (Quarterly) stood at -$243.9 million in 2021, then crashed by 84.42% to -$449.8 million in 2022, then slumped by 30.49% to -$587.0 million in 2023, then climbed by 16.68% to -$489.1 million in 2024, then increased by 29.54% to -$524.3 million in 2025.
- Its last three reported values are -$524.3 million in Q3 2025, -$570.7 million for Q2 2025, and -$591.4 million during Q1 2025.